Integral Diagnostics Stock

Integral Diagnostics EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Integral Diagnostics (IDX.AX) as of Aug 6, 2026 is 15.35. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 21.21 — a change of -27.66% (lower).

EV/EBIT

15.35

YoY

-27.66%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Integral Diagnostics is 2026 15.35 . EV/EBIT (Enterprise Value to EBIT) of Integral Diagnostics was 2025 21.21 . It decreases by -27.66% lower compared to the previous year.

The Integral Diagnostics EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
16.22 base
Jan 1, 2020
16.60 base
Jan 1, 2021
17.63 base
Jan 1, 2022
16.18 base
Jan 1, 2023
11.25 base
Jan 1, 2024
16.17 base
Jan 1, 2025
13.52 base
Jan 1, 2026 (e)
12.87 base
YEARPRICE-TO-EBIT
2026 est 12.87
2025 13.52
2024 16.17
2023 11.25
2022 16.18
2021 17.63
2020 16.60
2019 16.22
2018 14.00
2017 14.10
2016 6.34
2015 9.42
2014 -
2013 -
Access this data via the Eulerpool API

Integral Diagnostics Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Integral Diagnostics's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Integral Diagnostics's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Integral Diagnostics's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Integral Diagnostics grows earnings faster than its peers.

Integral Diagnostics Stock analysis

What does Integral Diagnostics do? Integral Diagnostics Ltd is an Australian company that has been providing medical imaging services for over 25 years. The company was founded in 1994 by Dr. Ian Kadish and a team of radiologists in Perth, Western Australia, offering radiology services to local clinics and hospitals. Over the years, Integral Diagnostics has expanded its services to provide imaging services nationwide. The business model of Integral Diagnostics is to deliver medical imaging to enable doctors and their patients to have a fast and accurate diagnosis. The company offers imaging services for a variety of medical specialties, including radiology, cardiology, obstetrics and gynecology, and neurology. They operate over 49 locations in Australia, many of which are in rural areas where access to medical care may be limited. Integral Diagnostics offers a wide range of products based on medical imaging. These include X-rays, mammography, ultrasound, CT scans, MRI scans, PET scans, and bone density scans. The company takes pride in being one of the few Australian medical imaging companies to offer a complete range of imaging services. Their services are conducted by qualified radiologists specialized in interpreting medical images. Integral Diagnostics also operates clinics for performing diagnostic and therapeutic procedures such as biopsies, drainages, and injections. These procedures are carried out by highly qualified radiologists to provide patients with faster and more accurate diagnoses. Integral Diagnostics is committed to quality assurance and has a comprehensive quality management system that is annually reviewed by independent auditors. The company is accredited by both the Australian Medical Association and the Australian National Accreditation Scheme (NATA). These accreditations recognize the high standards that Integral Diagnostics sets for delivering medical imaging services. One of Integral Diagnostics' recent activities is their use of artificial intelligence (AI) in image interpretation. The company has partnered with MaxQ AI, a leading provider of AI solutions for medical imaging. Through this partnership, Integral Diagnostics doctors can utilize the latest AI tools to improve their patients' diagnoses. Integral Diagnostics is a strong advocate for social justice and is dedicated to supporting disadvantaged communities in Australia. The company has partnered with nonprofit organizations such as the National Breast Cancer Foundation, The Smith Family, and the Friendship Foundation. Overall, Integral Diagnostics has undergone impressive growth over the past 25 years and is now a leading Australian medical imaging company. With a wide range of imaging services and a strong focus on quality and social responsibility, the company is well-positioned to continue its success in the future. Integral Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integral Diagnostics stock

EV/EBIT (Enterprise Value to EBIT) of Integral Diagnostics is 15.35 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Integral Diagnostics changed from 21.21 to 15.35, representing a -27.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Integral Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Integral Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Integral Diagnostics

All Key Metrics — Integral Diagnostics